The clinical pharmacology of integrase inhibitors

References

• Aronson JK. A manifesto for clinical pharmacology from principles to practice. Br J Clin Pharmacol. 2010 Jul;70(1):3–13.
   PubMed Web of Science ®Google Scholar
• Sc M, Wolters P, Calabrese S, et al. The Antiretroviral Regimen Complexity Index. A novel method of quantifying regimen complexity. J Acquir Immune Defic Syndr. 2007;45(5):535–544.
   PubMed Web of Science ®Google Scholar
• Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015 Feb;79(2):182–194.
   PubMed Web of Science ®Google Scholar
• Arts EJ, Hazuda DJ. HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161.
   PubMed Web of Science ®Google Scholar
• Zdanowicz MM. The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006 Oct 15;70(5):100.
   PubMed Web of Science ®Google Scholar
• Rosenbloom DI, Hill AL, Alireza Rabi SA, et al. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012 Sep;18(9):1378–1385.
   PubMed Web of Science ®Google Scholar
• Bezabhe WM, Chalmers L, Luke R, et al. Adherence to antiretroviral therapy and virologic failure. Medicine. 2016 Apr;95(15):e3361.
   PubMed Web of Science ®Google Scholar
• Bednasz CJ, Venuto CS, Ma Q, et al. Pharmacokinetic considerations for combining antiretroviral therapy, direct-acting antiviral agents for hepatitis C virus, and addiction treatment medications. Clin Pharmacol Drug Dev. 2017 Mar;6(2):135–139.
   PubMed Web of Science ®Google Scholar
• Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clinl Infect Dis. 2009;48:931–939.
   PubMed Web of Science ®Google Scholar
• Zuo X, Huo Z, Kang D, et al. Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017). Expert Opin Ther Pat. 2018;28(4):299–316.
   PubMed Web of Science ®Google Scholar
• Cited 2018 Aug 25. Available from: https://www.hiv-druginteractions.org
   Google Scholar
• At P, Kk S, Cv F. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017;56(1):25–40.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmacokinet. 2014 Oct;53(10):891–906.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017 May 1;75(1):61–66.
   PubMed Web of Science ®Google Scholar
• Cahn P, Sax PE, Squires K, et al. Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial. J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):589–598.
   PubMed Web of Science ®Google Scholar
• Cited 2018 Sep. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/04449/WC500250892.pdf
   Google Scholar
• Rizk MLKR, Schulz BBJ, Larson P, et al., editor. A multiple dose study of raltegravir formulations (Abstract 523). 21st CROI; 2014 March 3–6; Boston,MA. CROI Foundation/IAS–USA.
   Google Scholar
• Krishna RRM, Schulz V, Ingelse B, et al., editor. A single dose food effect study of raltegravir formulations. 14th European AIDS Conference; October 16–19, 2013; Brussels. (Abstract PE10/17). European AIDS Clinical Society.
   Google Scholar
• Eisfeld C, Reichelt D, Evers S, et al. CSF penetration by antiretroviral drugs. CNS Drugs. 2013 Jan;27(1):31–55.
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65–70.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Barco A, Trunfio M, et al. CNS-targeted antiretroviral strategies: when are they needed and what to choose. Curr HIV/AIDS Rep. 2018 Feb;15(1):84–91.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Simiele M, Alberione MC, et al. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Clin Infect Dis. 2015;60(2):311–317.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Simiele M, Motta I, et al. Elvitegravir/cobicistat/tenofovir/emtricitabine penetration in the cerebrospinal fluid of three HIV-positive patients. AIDS Res Hum Retroviruses. 2016 May;32(5):409–411.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Mills AM, Tashima KT, et al. NG116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014 Oct;59(7):1032–1037.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Thorkelson A, Winchester L, et al. Comparative lymphoid tissue pharmacokinetics (PKs) of integrase inhibitors (INSTI). 24h Conference on Retroviruses and Opportunistic Infections (CROI). March 4-7, 2018. Boston. Abstract 27. CROI Foundation/IAS–USA.
   Google Scholar
• Custodio JM Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Webcast presented at: conference on Retroviruses and Opportunistic Infections (CROI); February 13–16, 2017; Seattle, WA. CROI Foundation/IAS–USA.
   Google Scholar
• Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014 Jan;15(1):9–16.
   PubMed Web of Science ®Google Scholar
• Belkhir L, Seguin-Devaux C, Elens L, et al. Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Sci Rep. 2018 May 9;8(1):7359.
   PubMedGoogle Scholar
• Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201–1208.
   PubMed Web of Science ®Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agent Chemoter. 2009;53:2852–2856.
   PubMed Web of Science ®Google Scholar
• Dooley K, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21–27.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre,phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014;14:459–467.
   PubMed Web of Science ®Google Scholar
• Custodio JM, Sk W, Collins S, et al. Pharmacokinetics of Bictegravir administered twice daily in combination with Rifampicin. 25th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, March 4-7 2018, abstr. n. 34. CROI Foundation/IAS–USA.
   Google Scholar
• Custodio JM, West S, Lutz J, et al. Twice daily administration of tenofovir alafenamide in combination with rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection. 16th European AIDS Conference (EACS). October 25 –27 2017. Milan. Oral abstract PS13/4. European AIDS Clinical Society.
   Google Scholar
• Cerrone M, Alfarisi O, Neary M, et al. Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics. 25th CROI. Boston. 4–7 March 2018. Oral abstract 28LB. 2018 CROI Foundation/IAS–USA.
   Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52(12):4338–4343.
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Lou Y et al. Effects of enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, Dolutegravir (S/GSK1349572). 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami 2011; abstract O_02. Virology Education.
   Google Scholar
• Tivicay US Prescribing Information, Viiv Healthcare, June 2016.
   Google Scholar
• Zhang H, West S, Vu A, et al. Lack of clinically relevant effect of bictegravir on metformin pharmacokinetics and pharmacodynamics. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago, June 2017, abstract P_50. Virology Education.
   Google Scholar
• Biktarvy Prescribing Information, Gilead Sciences Inc, February 2018.
   Google Scholar
• Harea S, Vosb AM, Claytonb RF, et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. PNAS. 2010;107:20057–20062.
   PubMed Web of Science ®Google Scholar
• Thierry S, Munir S, Thierry E, et al. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration. Retrovirology. 2015 Mar 12;12:24.
   PubMed Web of Science ®Google Scholar
• White KL, Niedziela-Majka A, Nikolai Novikov N, et al. Bictegravir dissociation half-life from HIV-1 G140S + Q148H integrase/DNA complexes. 24th Conference on Retroviruses and Opportunistic Infections. Seattle, Feb 13-17, 2017. Abstr. n. 497. CROI Foundation/IAS–USA.
   Google Scholar
• Ke H, Wang R, Felix DeAnda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agent Chemoter. 2011;55:4552–4559.
   PubMed Web of Science ®Google Scholar
• Hurt CB, Sebastian J, Hicks CB, et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin Infect Dis. 2014;58(3):423–431.
   PubMed Web of Science ®Google Scholar
• Mata-Marín JA, Smeke AE, Rodriguez MR, et al. Effectiveness and risk factors for virological outcome of raltegravir-based therapy for treatment-experienced HIV-infected patients. Drugs R D. 2017;17(1):225–231.
   PubMed Web of Science ®Google Scholar
• Grobler JA, Dj H. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr Opin Virol. 2014 Oct;8:98–103.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Pulido F, García F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17(1):56–64.
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354–362.
   PubMed Web of Science ®Google Scholar
• Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086–7097.
   PubMed Web of Science ®Google Scholar
• Darcis G, Berkhout B. Human immunodeficiency virus resistance to dolutegravir: are we looking in the wrong place? J Infect Dis. 2018;218:2020.
   PubMed Web of Science ®Google Scholar
• Deeks ED, Raltegravir once-daily tablet: a review in HIV-1 infection. Drugs. 2017 Oct; 77(16):1789–1795
   PubMed Web of Science ®Google Scholar
• Siccardi M, DʼAvolio A, Rodriguez-Novoa S, et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit. 2012 Apr;34(2):232–235.
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Met Disp. 2007;35:1657–1663.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Bumpass JB, Meditz AL, et al. Effects of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agent Chemoter. 2010;54:4999–5003.
   PubMed Web of Science ®Google Scholar
• Arab-Alameddine M, Fayet-Mello A, Lubomirov R, et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agent Chemoter. 2012;56:2959–2966.
   PubMed Web of Science ®Google Scholar
• Brainard DM, Friedman EJ, Jin B, et al. Effect of low-moderate- and high fat meals on raltegravir pharmacokinetics. J Clin Pharmacol. 2011;51:422–427.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretrovral activity, pharmacokinetics and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. JAIDS. 2006;43:509–515.
   Google Scholar
• Iwamoto M, Wenning L, Petry A, et al. Safety, tolerability and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharm Ther. 2008;83:293–299.
   PubMed Web of Science ®Google Scholar
• Petry A, Wenning L, Laethem M, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects; 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006 Sep 27-30, 2006; San Francisco, CA. American Society for Microbiology.
   Google Scholar
• Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011 Dec;11(12):907–915.
   PubMed Web of Science ®Google Scholar
• Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naïve HIV-infected patients. Antimicrob Agents Chemother. 2012 Jun;56(6):3101–3106.
   PubMed Web of Science ®Google Scholar
• Krishna R, Rizk ML, Larson P, et al. Single- and multiple-dose pharmacokinetics of once-daily formulations of raltegravir. Clin Pharmacol Drug Dev. 2018 Feb;7(2):196–206.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Hanley WD, Petry AS, et al. Lack of clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agent Chemoter. 2009;53:1747–1752.
   PubMed Web of Science ®Google Scholar
• Molto J, Sanz-Moreno J, Valle M, et al. Minimal removal of raltegravir by hemodyalisis in HIB-infected patients with end-stage disease. Antimicrob Agent Chemoter. 2010;54:3047–3048.
   PubMed Web of Science ®Google Scholar
• Giguere P, La Porte C, Zhang G, et al. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on hemodialysis. Aids. 2009;23:740–742.
   PubMed Web of Science ®Google Scholar
• Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. [cited 2018 Sep]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
   Google Scholar
• IsentressR. Merck & Co. Inc. February: Whitehouse Station, NJ, 2015.
   Google Scholar
• Kearney B, Mathias A, Zhong L Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatment-naive and experienced patients. International Workshop on Clinical Pharmacology of HIV Therapy, 2006 Apr 20-22; Lisbon. Virology Education.
   Google Scholar
• German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010 Nov;55(3):323–329.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006 Sep;43(1):1–5.
   PubMed Web of Science ®Google Scholar
• German P, Warren D, Wei L, et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2009 Sep 12-15; San Francisco, CA. American Society for Microbiology.
   Google Scholar
• Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011 Jul;66(7):1567–72.
   Web of Science ®Google Scholar
• Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents; 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16-18;  Budapest, Hungary. Virology Education
   Google Scholar
• Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. J Acquir Immune Defic Syndr. 2015. DOI:10.1097/qai
   Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Elvitegravir. 2011. [cited 2018 Sep]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203100Orig1s000ClinPharmR.pdf.
   Google Scholar
• Custodio JM, Rhee M, Shen G, et al. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment. Antimicrob Agents Chemother. 2014 May;58(5):2564.
   PubMed Web of Science ®Google Scholar
• Momper JD, Bm B, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. Aids. 2018 Aug 20:1. Epub ahead of print. DOI: 10.1097/QAD.0000000000001992
   PubMed Web of Science ®Google Scholar
• Weller S, Chen S, Borland J, et al. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):393–398.
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. Aids. 2011;25(14):1737–1745.
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010 Jan;54(1):254–258.
   PubMed Web of Science ®Google Scholar
• Tivicay^R. ViiV Healthcare: Research Triangle Park. NC: Aug. 2015.
   Google Scholar
• Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012 Mar;56(3):1627–1629.
   PubMed Web of Science ®Google Scholar
• Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017 Sep 16;17(1):622.
   PubMedGoogle Scholar
• Borghetti A, Calcagno A, Lombardi F, et al. SLC22A2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptopms in HIV-positive patients on Dolutegravir. 19th International Workshop on Clinical Pharmacology of Antiviral Therapy. 2018 May 22-24; Baltimore, MD. Virology Education
   Google Scholar
• Cailhol J, Rouyer C, Alloui C, et al. Dolutegravir and neuropsychiatric adverse events: a continuing debate. Aids. 2017 Sep 10;31(14):2023–2024.
   PubMed Web of Science ®Google Scholar
• Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014 Jan;70(1):29–35.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Dolutegravir. 2013. [cited 2018 Sep]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000ClinPharmR.pdf.
   Google Scholar
• Song IH, Borland J, Savina PM, et al. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev. 2013 Oct;2(4):342–348.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Geneva, Switzerland. May 18, 2018.
   Google Scholar
• Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018 Jul;6(7):e804–e810.
   PubMed Web of Science ®Google Scholar
• Cited 2018 Sep. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002753/WC500160680.pdf
   Google Scholar
• Cited 2018 Sep. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004449/WC500250892.pdf
   Google Scholar
• Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 Aug 5;368(9534):466–475.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003 May 29;348(22):2186–2195.
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 Apr 7;369(9568):1169–1178.
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15(7):1045–1052.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 2;359(14):1429–1441.
   PubMed Web of Science ®Google Scholar
• Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 2015;20(3):343–348.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013 May 1;63(1):77–85.
   PubMed Web of Science ®Google Scholar
• Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet. 2001 Nov 24;358(9295):1760–1765.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Renaud Verdon R, Véronique Massari V. Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance. BMC Med Res Methodol. 2006;6:46.
   PubMedGoogle Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002 Jun 27;346(26):2039–2046.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 May 15;358(20):2095–2106.
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Aids. 2009 Aug 24;23(13):1679–1688.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010 Mar;53(3):323–332.
   PubMed Web of Science ®Google Scholar
• Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antivir Ther. 2011;16(3):339–348.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir‐lamivudine versus tenofovir‐emtricitabine for initial HIV‐1 therapy. N Engl J Med. 2009;361:2230–2240.
   PubMed Web of Science ®Google Scholar
• Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother. 2008;61:769–773.
   PubMed Web of Science ®Google Scholar
• Sl W, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014 Jun 28;383(9936):2222–2231.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014 Jul;14(7):581–589.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014 Jul;14(7):590–599.
   PubMed Web of Science ®Google Scholar
• Hodder S, Squires K, Kityo C, et al. Brief report: efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women. J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):209–213.
   PubMed Web of Science ®Google Scholar
• Shime N, Saito N, Bokui M, et al. Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections. Infect Drug Resist. 2018 Aug;6(11):1073–1081.
   Google Scholar
• Lewis PO, Heil EL, Covert KL, et al. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2018 Jul 12;43:614–625.
   Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605–612.
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2;381(9868):735–743.
   PubMed Web of Science ®Google Scholar
• Spivey JM. The postantibiotic effect. Clin Pharm. 1992 Oct;11(10):865–875.
   PubMedGoogle Scholar
• la Porte C. Inhibitory quotient in HIV pharmacology. Curr Opin HIV AIDS. 2008 May;3(3):283–287.
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Phillips AN, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Aids. 2008 Oct 18;22(16):2187–2198.
   PubMed Web of Science ®Google Scholar
• Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017 Jul 15;239:1–9.
   PubMed Web of Science ®Google Scholar
• Cahn P, Sierra Madero J, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naïve adults with HIV-1 infection - 48-week results from the GEMINI studies. Program and abstracts of the 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands. ( Abstract TUAB0106LB). IAS (International AIDS Society).
   Google Scholar
• Valantin MAS, Lambert-Niclot P, Flandre L, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012;67:691–695.
   PubMed Web of Science ®Google Scholar
• Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14:572–580.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017;72:1163–1171.
   PubMed Web of Science ®Google Scholar
• Sued O, Figueroa MI, Gun A, et al. Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study. 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Abstract MOAB0106LB. IAS (International AIDS Society).
   Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018 Mar 3;391(10123):839–849.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145–1155.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
   PubMed Web of Science ®Google Scholar